Apellis Pharmaceuticals, Inc. (APLS)
40.90
+0.03
(+0.07%)
USD |
NASDAQ |
Apr 17, 16:00
40.90
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals SG&A Expense (Quarterly) : 147.10M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Biogen, Inc. | 682.50M |
| Eli Lilly & Co. | 3.132B |
| Agios Pharmaceuticals, Inc. | 51.61M |
| Scholar Rock Holding Corp. | 45.02M |
| Kezar Life Sciences, Inc. | 3.248M |